Carr Douglas, Century Therapeutics’ SVP Finance & Operations, sold 254 shares at $2.05 per share on 2026-09-08. The transaction represented about 0.1% of Douglas’s prior shareholding, while his reported position after the sale was 504,565 shares, giving investors the disclosed scale of the executive ownership change.
Key Highlights
- The filing reported SEC transaction code S for Carr Douglas’s sale.
- Douglas held 504,565 Century Therapeutics shares after the transaction.
- The sale represented about 0.1% of Douglas’s prior shareholding.
Carr Douglas, SVP Finance & Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), sold 254 shares at $2.05 per share. The transaction occurred on 8 September 2026 and left Douglas holding 504,565 Century Therapeutics shares.
Sale Involves 254 Shares
Carr Douglas serves as Century Therapeutics’ SVP Finance & Operations. The filing reported SEC transaction code S for the trade. The disclosed price was measured per share, while the transaction size was 254 shares. After the sale, Douglas’s reported Century Therapeutics position stood at 504,565 shares. The transaction therefore involved a defined number of shares transferred at a stated per-share price.
Sale Equals About 0.1% of Prior Holding
The transaction represented about 0.1% of Douglas’s prior shareholding. That percentage measures the sale against the position held before the transaction. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Century Therapeutics shares did Carr Douglas sell?
A: Carr Douglas sold 254 Century Therapeutics shares at $2.05 per share. The transaction took place on 8 September 2026 and was classified with SEC transaction code S.
Q: What was the impact of Carr Douglas’s Century Therapeutics stock sale?
A: Carr Douglas’s sale represented about 0.1% of his prior Century Therapeutics shareholding. After the transaction, which involved 254 shares, his reported position stood at 504,565 Century Therapeutics shares.
Q: What does transaction code S mean for the IPSC stock transaction?
A: The filing reported SEC transaction code S for Carr Douglas’s sale. The supplied filing information does not provide a further description of what that code means.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.